Follow
Matthias Holdhoff
Title
Cited by
Cited by
Year
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
59502017
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
46472014
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Y Jiao, PJ Killela, ZJ Reitman, BA Rasheed, CM Heaphy, RF De Wilde, ...
Oncotarget 3 (7), 709, 2012
6802012
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord
Y Wang, S Springer, M Zhang, KW McMahon, I Kinde, L Dobbyn, J Ptak, ...
Proceedings of the National Academy of Sciences 112 (31), 9704-9709, 2015
4202015
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
JD Phelan, RM Young, DE Webster, S Roulland, GW Wright, M Kasbekar, ...
Nature 560 (7718), 387-391, 2018
3372018
Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology
LB Nabors, J Portnow, M Ahluwalia, J Baehring, H Brem, S Brem, ...
Journal of the National Comprehensive Cancer Network 18 (11), 1537-1570, 2020
3232020
NCCN guidelines insights: central nervous system cancers, version 1.2017
LB Nabors, J Portnow, M Ammirati, J Baehring, H Brem, N Butowski, ...
Journal of the National Comprehensive Cancer Network 15 (11), 1331-1345, 2017
272*2017
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
J Rodon, MA Carducci, JM Sepulveda-Sánchez, A Azaro, E Calvo, ...
Clinical Cancer Research 21 (3), 553-560, 2015
2462015
Systemic use of tumor necrosis factor alpha as an anticancer agent
NJ Roberts, S Zhou, LA Diaz Jr, M Holdhoff
Oncotarget 2 (10), 739, 2011
2112011
Ivosidenib in isocitrate dehydrogenase 1–mutated advanced glioma
IK Mellinghoff, BM Ellingson, M Touat, E Maher, I Macarena, M Holdhoff, ...
Journal of clinical oncology 38 (29), 3398, 2020
1922020
Central nervous system cancers
LB Nabors, M Ammirati, PJ Bierman, H Brem, N Butowski, ...
Journal of the National Comprehensive Cancer Network 11 (9), 1114-1151, 2013
1712013
High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma
M Holdhoff, P Ambady, A Abdelaziz, G Sarai, D Bonekamp, J Blakeley, ...
Neurology 83 (3), 235-239, 2014
1532014
Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging: a validation study with image-guided stereotactic biopsy
S Jiang, CG Eberhart, M Lim, HY Heo, Y Zhang, L Blair, Z Wen, ...
Clinical Cancer Research 25 (2), 552-561, 2019
1272019
Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations
M Holdhoff, K Schmidt, R Donehower, LA Diaz
JNCI: Journal of the National Cancer Institute 101 (18), 1284-1285, 2009
1152009
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced …
J Rodón, M Carducci, JM Sepulveda-Sánchez, A Azaro, E Calvo, ...
Investigational new drugs 33, 357-370, 2015
1132015
Central nervous system cancers, version 1.2015
LB Nabors, J Portnow, M Ammirati, J Baehring, H Brem, P Brown, ...
Journal of the National Comprehensive Cancer Network 13 (10), 1191-1202, 2015
1122015
Vorasidenib in IDH1-or IDH2-mutant low-grade glioma
IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ...
New England Journal of Medicine 389 (7), 589-601, 2023
1062023
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor
M Holdhoff, KA Kreuzer, C Appelt, R Scholz, IK Na, B Hildebrandt, ...
Blood Cells, Molecules, and Diseases 34 (2), 181-185, 2005
1032005
Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
KC Schreck, S Ranjan, N Skorupan, C Bettegowda, CG Eberhart, ...
Journal of neuro-oncology 143, 87-93, 2019
942019
MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas
N Nayyar, MD White, CM Gill, M Lastrapes, M Bertalan, A Kaplan, ...
Blood advances 3 (3), 375-383, 2019
882019
The system can't perform the operation now. Try again later.
Articles 1–20